This study aims to validate the regenerative potential of chimeric fibroblast growth factor 21 (FGF21) and Hepatocyte Growth Factor Receptor (HGFR) in NAFLD-afflicted liver cells. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.